CHALKBOARD ENTRY 01 — MEHFPGP
Semax is a Russian heptapeptide developed from the ACTH 4-10 fragment for stroke recovery and cognition.
A literature digest — the Pro-Gly-Pro tail, the intranasal route, the BDNF and NGF upregulation, and what fifty years of Russian neurochemistry actually shows.
What is Semax? The Russian Heptapeptide
Semax is a synthetic heptapeptide — seven amino acids in sequence, Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP. The first four residues (Met-Glu-His-Phe) are lifted directly from positions 4-7 of adrenocorticotropic hormone (ACTH). The last three (Pro-Gly-Pro) are a synthetic stabilizing tail, added in Moscow in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences [1].
That tail does two things at once. It protects the peptide from being chewed up by plasma peptidases — bare ACTH 4-10 has a half-life measured in seconds. And it removes the corticotropic activity of the parent ACTH hormone. Semax engages the brain pathways the 4-10 fragment can reach, without driving cortisol release [2].
The molecule was first described by Potaman and colleagues in 1991. It was registered on Russia's List of Vital and Essential Drugs in 2011 — approved there as a prescription medication for ischemic stroke recovery, optic nerve disease, and cognitive disorders. It has never been approved by the FDA, the EMA, or any Western regulator. The Western literature is largely mechanistic — rat models, in-vitro work, and reviews of the Russian clinical data.
Why is Semax studied?
Across rodent and clinical studies, Semax produces a reproducible cluster of effects: rapid upregulation of brain-derived neurotrophic factor (BDNF) and its TrkB receptor in the hippocampus and basal forebrain [3], increased nerve growth factor (NGF) gene expression in frontal cortex and retina [4], attenuation of pathological nitric oxide overproduction in the ischemic cortex [5], and activation of striatal serotonergic and dopaminergic systems within hours of administration [6].
In the published clinical record, the most-cited Western-facing trial is Gusev and Skvortsova 1997 — intranasal Semax added to standard care in 30 patients during the acute period of hemispheric ischemic stroke, compared to 80 conventional-therapy controls. The Semax arm showed faster regression of motor and general cerebral deficits, with electrophysiological improvement [7].
That is the headline. The substrate is fifty years of Russian neurochemistry, concentrated in a small number of research groups — Myasoedov, Skvortsova, Dergunova, Bashkatova. Western replication is thin. The peptide is real, the mechanism is reproducible, the clinical evidence is single-country.
Semax as a Nootropic in Russian Clinical Use
Russian pharmacological literature classifies Semax as a nootropic — a class behaviorally defined by improvement in cognitive performance (attention, memory consolidation, learning) without classical stimulant action [8]. Semax is not a CNS stimulant. It does not act through catecholamine release. The cognitive signal in published work appears to be downstream of BDNF and NGF upregulation, with downstream serotonergic and dopaminergic modulation playing a secondary role.
In Russian clinical practice, intranasal courses have been used for chronic cerebrovascular insufficiency, post-stroke cognitive recovery, attention deficits in pediatric populations, and optic-nerve atrophy [9]. The nootropic framing — improvement in healthy adults — rests mostly on the rodent BDNF data plus extrapolation from clinical populations. Western placebo-controlled cognition trials in healthy volunteers do not exist in the peer-reviewed record at the time of writing.
For a head-to-head with the other Russian Institute of Molecular Genetics peptide, see Semax vs Selank. For the user-experience reports framed through the trial record, see Semax reviews.
How this site reads the record
Every quantitative claim on this site is cited to a paper listed on the references page. The dose ranges, half-life numbers, BDNF binding constants, and clinical outcomes come from named publications — most from PubMed-indexed entries, some from Russian-language journals identified by PMID where DOI assignment pre-dates the index. The full Semax dosage reading covers the intranasal protocol, the rodent dose ranges, and the pharmacokinetic-pharmacodynamic gap. The Semax mechanism of action reading walks through BDNF, NGF, the ACTH 4-10 lineage, and the more recent 2024-2025 work on the mu opioid receptor and intracellular calcium dynamics.
This site is editorial. It is not a clinic, it does not sell anything, and it does not provide medical advice. For frequently asked questions about Semax — legality, storage, hormones, stacking — the FAQ index is the entry point.